Last €38.48 EUR
Change Today +0.80 / 2.11%
Volume 1.3M
FRE On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
Xetra
As of 3:45 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

fresenius se & co kgaa (FRE) Snapshot

Open
€37.64
Previous Close
€37.68
Day High
€38.67
Day Low
€37.64
52 Week High
02/17/14 - €40.20
52 Week Low
11/4/13 - €31.02
Market Cap
20.8B
Average Volume 10 Days
1.7M
EPS TTM
€2.01
Shares Outstanding
541.2M
EX-Date
05/19/14
P/E TM
19.1x
Dividend
€0.42
Dividend Yield
1.08%
Current Stock Chart for FRESENIUS SE & CO KGAA (FRE)

Related News

No related news articles were found.

fresenius se & co kgaa (FRE) Related Businessweek News

No Related Businessweek News Found

fresenius se & co kgaa (FRE) Details

Fresenius SE & Co. KGaA provides products and services for dialysis, hospital, and outpatient medical care worldwide. Its Fresenius Medical Care segment provides products for hemodialysis and peritoneal dialysis; and dialysis care services at its clinics. This segment also offers dialyzers, dialysis machines, and renal pharmaceuticals; and performs clinical laboratory tests. As of December 31, 2013, it treated patients with approximately 3,250 dialysis clinics. The company's Fresenius Kabi segment offers therapy and care products for chronically and critically ill patients. This segment provides intravenously administered generic drugs, such as anesthetics, anti-infectives, and analgesics, as well as drugs for the treatment of oncological and other critical diseases; infusion solutions and blood volume replacement products for infusion therapy; parenteral and enteral nutrition products; infusion and nutrition pumps; and transfusion technology comprising products that are used in the collection and processing whole blood and blood components, as well as in transfusion medicine. Its Fresenius Helios segment operates approximately 74 hospitals, including 51 acute care hospitals and 23 post acute care clinics; 35 outpatient facilities; and 13 nursing homes with approximately 23,000 beds. The company's Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers planning and construction services for turnkey construction projects, and medical-technical and building utilities, as well as executes projects as general contractor; and provides technical facility and operational management services, as well as replacement parts sourcing services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

209,933 Employees
Last Reported Date: 08/5/14
Founded in 1912

fresenius se & co kgaa (FRE) Top Compensated Officers

Chairman of the Management Board - Fresenius ...
Total Annual Compensation: €2.4M
Chief Financial Officer of Fresenius Manageme...
Total Annual Compensation: €1.5M
Chief Executive Officer of Fresenius Kabi
Total Annual Compensation: --
Chief Legal & Compliance Officer of Fresenius...
Total Annual Compensation: €1.1M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €1.5M
Compensation as of Fiscal Year 2013.

fresenius se & co kgaa (FRE) Key Developments

Fresenius, PE Firms Reportedly Eye Danone's Medical Nutrition Unit

Fresenius SE & Co KGaA (DB:FRE) and private equity houses PAI Partners and Permira Advisers Ltd. are reportedly weighing bids for the medical nutrition unit of Danone (ENXTPA:BN), sources familiar with the situation told Reuters. Fresenius sought to take over the division earlier in 2014 but withdraw from the deal as it considered the price asked to be too high, sources told Reuters. Any agreement is still months away as the transaction is considered a complex one, the news agency noted. PAI is ready to strike any deal for the division along with co-investors, one of the sources added. All companies mentioned declined to comment when contacted by Reuters.

Fresenius In Advanced Talks To Buy Danone's Medical Nutrition Business

Danone (ENXTPA:BN) is in advanced talks to sell its medical nutrition unit to Fresenius SE & Co KGaA (DB:FRE) in a deal that could value the business at about €3 billion, according to people familiar with the matter. A deal could be announced in the next few weeks, but the people familiar with the deal cautioned that talks could still fall apart. Danone and Fresenius declined to comment. Nestlé S.A. (SWX:NESN) and Hospira Inc. (NYSE:HSP) had previously been in talks for the Danone unit.

Fresenius SE & Co KGaA Presents at Credit Suisse Global Credit Products Conference, Sep-18-2014

Fresenius SE & Co KGaA Presents at Credit Suisse Global Credit Products Conference, Sep-18-2014 . Venue: Fontainebleau Miami Beach, 4441 Collins Avenue, Miami Beach, FL 33140, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRE:GR €38.48 EUR +0.80

FRE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $56.90 USD +0.21
Covidien PLC $88.45 USD +1.04
Danone SA €51.03 EUR +0.43
DaVita HealthCare Partners Inc $76.25 USD +0.97
Mead Johnson Nutrition Co $100.66 USD +0.73
View Industry Companies
 

Industry Analysis

FRE

Industry Average

Valuation FRE Industry Range
Price/Earnings 17.9x
Price/Sales 0.9x
Price/Book 2.2x
Price/Cash Flow 17.9x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS SE & CO KGAA, please visit www.fresenius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.